PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

por Zeidan, Amer M, Fathi, Amir, Issa, Ghayas, Erba, Harry, Mackey, Julie Ahsan, Corum, Daniel, Tomkinson, Blake, Kozlek, Tom, Leoni, Mollie, Wang, Eunice
Publicado 2023

PDE5 inhibition rescues mitochondrial dysfunction and angiogenic responses induced by Akt3 inhibition by promotion of PRC expression

por Corum, Daniel G., Jenkins, Dorea P., Heslop, James A., Tallent, Lacey M., Beeson, Gyda C., Barth, Jeremy L., Schnellmann, Rick G., Muise-Helmericks, Robin C.
Publicado 2021

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans

por Rotroff, Daniel M., Oki, Noffisat O., Liang, Xiaomin, Yee, Sook Wah, Stocker, Sophie L., Corum, Daniel G., Meisner, Michele, Fiehn, Oliver, Motsinger-Reif, Alison A., Giacomini, Kathleen M., Kaddurah-Daouk, Rima
Publicado 2016

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

por Fathi, Amir, Wang, Eunice, Issa, Ghayas, Altman, Jessica, Montesinos, Pau, de Botton, Stéphane, Walter, Roland, Pettit, Kirsten, Patnaik, Mrinal, Kremyanskaya, Marina, Baer, Maria, M Foran, James, Schiller, Gary, Ades, Lionel, Heiblig, Maël, Peterlin, Pierre, Salamero Garcia, Olga, Papayannidis, Cristina, Nie, Kun, Ahsan Mackey, Julie, Tabachri, Marilyn, Corum, Daniel, Leoni, Mollie, Dale, Stephen, Erba, Harry
Publicado 2023